By NewsDesk  @infectiousdiseasenews Morristown, NJ pharmaceutical company, Melinta Therapeutics announced this week that their lipoglycopeptide antibiotic, KIMYRSA™ (oritavancin), is now commercially...

Melinta Therapeutics, LLC (Melinta), today announced that the U.S. Food and Drug Administration (FDA) has approved KIMYRSA™ (oritavancin)  for the treatment of adult patients with acute bacterial skin...

By

The U.S. Food and Drug Administration today approved Orbactiv (oritavancin), a new antibacterial drug to treat adults with skin infections. Orbactiv is approved to treat patients with acute bacterial skin...